Isomorphic Labs raises $5 billion in its second mega-round within six months

Company news The Decoder Source language: English

Isomorphic Labs has raised $5 billion, just six months after a $2.1 billion round. Alphabet's AI drug discovery company, led by Demis Hassabis, plans to use the funding to push its drug pipeline toward clinical trials.

Full text

Short News

Isomorphic Labs raises $5 billion in its second mega-round within six months

Maximilian Schreiner View the LinkedIn Profile of Maximilian Schreiner

Nov 17, 2026

Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months. Greenoaks and Sequoia Capital co-led the round, joined by new backer Andreessen Horowitz along with Alphabet and all existing investors.

The company had already raised $2.1 billion back in May 2026. The money will go toward advancing its in-house platform IsoDDE (Isomorphic Drug Design Engine) and pushing its drug pipeline toward clinical trials. IsoDDE goes beyond AlphaFold 3, according to the company founded in 2021, and aims to better predict drug binding and docking sites. Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug to show for it yet.

The company is led by Demis Hassabis, who stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet's Chief Scientist. Hassabis won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold.

Deepmind's original AlphaFold team was disbanded in July 2026. Many researchers moved to Isomorphic Labs or were reassigned to other projects. Nearly a quarter left Deepmind entirely. Deepmind still shipped AlphaGenome 2 in early November 2026, which predicts how DNA variants affect gene activity in specific cell types.

Sources

← Back to the daily brief